PEComa of the Upper Extremity: A Unique Case and Description of an Initial Response to Neoadjuvant Chemotherapy by Osei, D. A. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2007, Article ID 53056, 3 pages
doi:10.1155/2007/53056
CaseReport
PEComa of the Upper Extremity: A Unique Case
and Description of an Initial Response to
Neoadjuvant Chemotherapy
D. A. Osei,1 F. Alvandi,2 J. S. Brooks,2 and C. M. Ogilvie3
1University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
2Department of Pathology, Pennsylvania Hospital, University of Pennsylvania Health Systems, PA 19107, USA
3Department of Orthopaedic Surgery, Pennsylvania Hospital, University of Pennsylvania Health Systems, PA 19106, USA
C o r r e s p o n d e n c es h o u l db ea d d r e s s e dt oC .M .O g i l v i e ,christian.ogilvie@uphs.upenn.edu
Received 2 September 2005; Revised 1 June 2007; Accepted 15 August 2007
Recommended by Raphael E. Pollock
Purpose. Tumors of the perivascular epithelial cell tumor (PEComa), ﬁrst described in 1992, represent a rare soft tissue neoplasm
of varying malignant potential. Cases of PEComa have been previously described in a few somatic and visceral sites, most notably
in the gastrointestinal tract, genitourinary tract, and one extremity case in the thigh. To date, most malignant cases of PEComa
have been resistant to chemotherapy, and as such, an appropriate therapy is not known. Case report.H e r ew ed e s c r i b et h eﬁ r s tc a s e
of PEComa of the upper extremity. Open biopsy revealed a high-grade malignant lesion, and the patient subsequently underwent
both neoadjuvant therapy with doxorubicin, ifosfamide and mensa, and radiation therapy prior to wide surgical resection. After
sixcyclesofchemotherapy,thetumorunderwentan80%reductioninsize.Subsequentneoadjuvantradiationtherapyof5000cGy
did not further reduce the size of the tumor. Following limb sparing radical resection, pathology showed 20% necrosis within a
high-grade malignant lesion. Twenty one months after beginning treatment, the patient shows no sign of local recurrence, but
metastatic disease was conﬁrmed after resection of a lung nodule. Conclusion. Given the favorable albeit partial response seen in
this patient, the course of therapy outlined here may represent a good starting point for neoadjuvant treatment in a tumor with a
historically bleak prognosis. In addition, the diagnosis of PEComa must now be entertained in the diﬀerential diagnosis of upper
extremity soft tissue sarcoma.
Copyright © 2007 D. A. Osei et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Perivascular epitheloid cell tumor, or PEComa, is a rare soft
tissue tumor characterized by cells epitheloid in morphol-
ogy with clear or eosinophilic cytoplasm, and a perivascu-
lar distribution. Immunohistologically, PEComa is deﬁned
by positive staining for the melanocytic marker HMB-45
and smooth muscle actin (SMA), but negative staining for
melanocytic marker S100 and variable staining for MelanA.
First described in 1992 by Bonetti et al. [1], PEComas have
since been reported involving the bladder, colon, falciform
ligament, uterus, kidney, skull, and the thigh [2–8]. PEComa
exhibitsawidevarietyofbehavior,frombenigndiseasetreat-
able by excision alone, to most recently described malignant
disease with a poor chemotherapeutic response and prog-
nosis [6]. There is no established treatment for malignant
PEComa as most regimens, based on chemotherapeutic re-
sponses of similar tumors such as clear cell sarcoma of soft
parts (CCSSP) and GI stromal tumors (GIST), have largely
been unsuccessful.
In this article, we present the ﬁrst reported case of a
PEComaoftheupperextremity.Wealsoreportanencourag-
ing response to doxorubicin-ifosfamide (Dox-Ifos), allowing
for a more manageable deﬁnitive treatment with tumor exci-
sion.
2. CASE REPORT
A 49-year-old female presented in April 2004 with a mass
on the back of her right shoulder and complaints of wors-
ening pain with activity and decreased ROM. The patient
underwent MRI and CT imaging of her right scapula which2 Sarcoma
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Figure 1: CT scan of the right scapula demonstrating a tumor in




Figure 2: MRI of the right scapula showing a decrease in size of
the PEComa after completion of neoadjuvant treatment (arrow).
Edema of the surrounding infraspinatus muscle is evident as a
bright area with less distinct boundaries than the tumor.
revealed an abnormal 5.3 × 4 . 7 c ms o f tt i s s u em a s si nt h e
posterior medial aspect of the infraspinatus muscle. (see
Figure 1) The mass was hypointense on T1, hyperinterense
on T2, and was associated with prominent surrounding
edema and signiﬁcant inﬁltration into the surrounding soft
tissue. Biopsy of the mass in May 2004 revealed a high-grade
malignant PEComa, largely undiﬀerentiated and pleomor-
phic. Immunostaining of the tumor revealed strong positiv-
ity for Melan-A, no expression of S-100 or tyrosinase, and
focal expression of HMB-45 and smooth muscle actin. The
cells exhibited striking cytologic atypia and focal islands of
necrosis, supporting the diagnosis of a high-grade malignant
sarcoma. TNM staging determined by biopsy and imaging
was T2bN0M0. Pathology consultation was sought from Dr.
S. Weiss (Emory University), and yielded the same diagnosis.
The patient began neoadjuvant therapy in May 2004, re-
ceiving six cycles of doxorubicin and ifosfamide (Dox-Ifos)
between 5/10/04 and 9/10/04. Postchemotherapy MRI re-
vealed an 80.1% decrease in size of the tumor to 3.3cm
× 1.5cm. Subsequently, the patient underwent preopera-
tive radiation therapy of the eﬀected area consisting of ﬁve
treatments per week for ﬁve weeks between 10/19/04 and
11/24/04 for a total of 5000cGy. Postradiation MRI revealed
an increase in the size of the mass of 45.5% to 4.0cm ×
1.8cm (see Figure 2).
Limb sparing wide resection of the shoulder mass was
performed on 12/20/04. Examination of the pathology spec-
imen conﬁrmed the diagnosis of malignant PEComa, with
negative margins. The specimen revealed only 20% necrosis
at the time of removal.
3. FOLLOWUP
On followup four months after the last chemotherapy treat-
ment, the patient showed no evidence of disease on MRI.
The patient’s chief complaint of arm pain continued to im-
prove.Thepatientexhibitednoconstitutionalsymptomsand
was advised to continue to followup with repeat MRI of
the scapula and Ct of the chest every three months for the
ﬁrst two years. The patient has no local recurrence thirteen
months postresection (as of 1/06), but she did have a solitary
lung mass on her chest CT at that same time. This lung mass
excised fourteen months after removal of her primary lesion
and was conﬁrmed to be a metastasis.
4. DISCUSSION
PEComas are soft tissue tumors deﬁned by their unique ex-
pression of both melanocytic and smooth muscle cell mark-
ers. Radial arrangement of epithelioid cells around a vascular
lumenischaracteristicinthesetumors,althoughtherecanbe
variationintherelativeproportionofepithelioidversusspin-
dled cells. The group of tumors that share this “perivascular
epithelioid cell (PEC)” nature is heterogeneous and includes
the following: lymphangiomyomatosis, pulmonary and ex-
trapulmonary clear cell sugar tumor, clear cell melanomy-
ocytic tumor, and abdominopelvic sarcoma of the perivas-
cular cells, perivascular epithelioid cell tumor (PECT) [9].
This tumor appears to have some predilection for female in
their ﬁrst-to-fourth decades. There has been a reported as-
sociation with the tuberous sclerosis complex, but the vast
majority of cases have been idiopathic. Because so little is
known about the biology and natural history of this tumor,
there is no established consensus regarding treatment. While
most PEComa are benign, there have been several described
cases of malignant or metastatic PEComa, most resulting in
death after failing to respond to treatment. Features of ma-
lignancy include hypercellularity, high mitotic rate, presence
of atypical mitotic ﬁgures, necrosis, and inﬁltrative growth
pattern [9]. Rigby et al. recently described a failed attempt
at treatment of a metastatic renal PEComa with DTIC and
imatinib based on treatment of similar tumors and expres-
sion of c-kit [6]. Several cases of PEComa arising secondary
to dediﬀerentiationofangiomyolipoma havebeendescribed,
with variable response rates to doxorubicin and CyVADIC
(cyclophosphamide, vincristine, epidoxorubicin, and dacar-
bazine) [10, 11]. For soft tissue sarcoma of the extremity,
the mainstay of treatment continues to be surgical resec-
tionandradiation+/−chemotherapy.Inthiscase,aregimenD. A. Osei et al. 3
including all of these modalities was believed to oﬀer the best
chance for a disease-free outcome.
Forourpatient,doxorubicin,ifosfamide,andmensawere
used as neoadjuvant therapy. These agents have been shown
in numerous studies to be among the most eﬃcacious in
the treatment of adult soft tissue sarcoma [12–17]. Overall
response rates to doxorubicin and ifosfamide have been re-
ported as 21% and 28%, respectively [18]. The combination
of the two drugs (Dox-Ifos) has been reported to be as high
as 34–41% in various trials [19]. Here we present a case of
a robust initial response by a high-grade malignant PEComa
to this regimen, which to our knowledge, has not been de-
scribed previously. Oddly enough, this response was not re-
ﬂected in the posttreatment resection where there was only
20% necrosis. Despite this initial clinical response, our pa-
tient developed a single lung metastasis sixteen months after
chemotherapy. Given the history of poor responses and out-
comes of these tumors to other regimens, we believe that this
case may represent a model by which future treatment may
be designed.
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